Cheaper hepatitis drug to be offered

Gilead Sciences Inc. will sell cheaper versions of its blockbuster hepatitis C drugs, the original versions of which sparked widespread debate about U.S. pharmaceutical costs when they were introduced at a price of more than $1,000 a pill.

The new, cheaper versions of Gilead’s Epclusa and Harvoni will cost $24,000 for a course of treatment, the Foster City, Calif.-based company said in a statement Monday. When Harvoni came on the market in 2014, Gilead set a list price of $94,500. Epclusa was approved for sale in 2016, with a price of $74,760.

Gilead, like almost all pharmaceutical companies, offers discounts on the sticker price of its treatments, but those discounts aren’t always passed on to patients.

The company said that dynamic and complicated insurance contracts were the reason it was forming a new business unit to offer versions of the drug at lower list prices.

Gilead’s hepatitis C drugs remain among the bestselling pharmaceutical products in history, and have helped boost the company’s market valuation to almost $100 billion. The drugs also made Gilead the subject of congressional hearings and accusations of pharmaceutical greed.

The therapies were the first to market among a new class of hepatitis C drugs that cure patients of the illness, with fewer side effects than older therapies.

Despite their effectiveness, some insurance companies and government health programs limited early access to the drugs because of the cost.

After Gilead’s drugs came to market, subsequent rival treatments from AbbVie Inc. and other companies arrived and drove down the price of the therapies.

Gilead’s new drugs will be sold through a new subsidiary called Asegua Therapeutics.